{"title":"西罗多辛在治疗男性前列腺良性增生下尿路症状中的应用:“现实生活”中的标准方法和应用","authors":"A. Alcántara Montero","doi":"10.1016/j.uromx.2016.09.005","DOIUrl":null,"url":null,"abstract":"<div><p>Lower urinary tract symptoms (LUTS) are very frequent in men, especially in those above 65 years of age. Benign prostatic hyperplasia (BPH) is the pathology most associated with LUTS in men and is a frequent cause of altered quality of life. Monotherapy with alpha blockers is the treatment of choice in patients with moderate-to-severe LUTS secondary to BPH.</p><p>Silodosin is currently the most uroselective alpha blocker acting on the α1A receptors. Its uroselectivity has been confirmed in different <em>in vitro</em>, as well as <em>in vivo</em>, studies. The present study analyzed the main benefits of silodosin in phase <span>iii</span> clinical trials (standard approach) and in «real life» (analyzing the «Silodosin in Real-life Evaluation (SiRE)» phase <span>iv</span> trial) to validate the registrational trials and confirm the positive risk-benefit profile of silodosin in an environment that can more closely reflect clinical practice.</p></div>","PeriodicalId":34909,"journal":{"name":"Revista mexicana de urologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uromx.2016.09.005","citationCount":"1","resultStr":"{\"title\":\"Silodosina en el tratamiento de los síntomas del tracto urinario inferior en el varón por hiperplasia benigna de próstata: enfoque estándar y uso en la «vida real»\",\"authors\":\"A. Alcántara Montero\",\"doi\":\"10.1016/j.uromx.2016.09.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Lower urinary tract symptoms (LUTS) are very frequent in men, especially in those above 65 years of age. Benign prostatic hyperplasia (BPH) is the pathology most associated with LUTS in men and is a frequent cause of altered quality of life. Monotherapy with alpha blockers is the treatment of choice in patients with moderate-to-severe LUTS secondary to BPH.</p><p>Silodosin is currently the most uroselective alpha blocker acting on the α1A receptors. Its uroselectivity has been confirmed in different <em>in vitro</em>, as well as <em>in vivo</em>, studies. The present study analyzed the main benefits of silodosin in phase <span>iii</span> clinical trials (standard approach) and in «real life» (analyzing the «Silodosin in Real-life Evaluation (SiRE)» phase <span>iv</span> trial) to validate the registrational trials and confirm the positive risk-benefit profile of silodosin in an environment that can more closely reflect clinical practice.</p></div>\",\"PeriodicalId\":34909,\"journal\":{\"name\":\"Revista mexicana de urologia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.uromx.2016.09.005\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista mexicana de urologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2007408516300726\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista mexicana de urologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2007408516300726","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Silodosina en el tratamiento de los síntomas del tracto urinario inferior en el varón por hiperplasia benigna de próstata: enfoque estándar y uso en la «vida real»
Lower urinary tract symptoms (LUTS) are very frequent in men, especially in those above 65 years of age. Benign prostatic hyperplasia (BPH) is the pathology most associated with LUTS in men and is a frequent cause of altered quality of life. Monotherapy with alpha blockers is the treatment of choice in patients with moderate-to-severe LUTS secondary to BPH.
Silodosin is currently the most uroselective alpha blocker acting on the α1A receptors. Its uroselectivity has been confirmed in different in vitro, as well as in vivo, studies. The present study analyzed the main benefits of silodosin in phase iii clinical trials (standard approach) and in «real life» (analyzing the «Silodosin in Real-life Evaluation (SiRE)» phase iv trial) to validate the registrational trials and confirm the positive risk-benefit profile of silodosin in an environment that can more closely reflect clinical practice.
期刊介绍：
Revista Mexicana de Urología (RMU) [Mexican Journal of Urology] (ISSN: 0185-4542 / ISSN electronic: 2007-4085) is bimonthly publication that disseminates research by academicians and professionals of the international medical community interested in urological subjects, in the format of original articles, clinical cases, review articles brief communications and letters to the editor. Owing to its nature, it is publication with international scope that disseminates contributions in Spanish and English that are rigorously reviewed by peers under the double blind modality. Neither journalistic documents nor those that lack rigorous medical or scientific support are suitable for publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
